Global Alzheimer's Platform Foundation

Recent papers from Global Alzheimer's Platform Foundation

1. Genetic Resilience and Resistance in Alzheimer's Disease Diagnosis and PathologyAnnals of Neurology · 2026
2. Antemortem α-Synuclein levels from neuron-derived extracellular vesicles identify Lewy Body pathology in Parkinson’s Disease and Alzheimer Disease2026
3. Multicenter validation of plasma p‐tau217/ amyloid beta 1‐42 ratio in symptomatic Alzheimer's diseaseAlzheimer s & Dementia · 2026
4. Inflammation profiles in Alzheimer's disease relate to cognition and neurodegenerationAlzheimer s & Dementia · 2026
5. Blood biomarkers to improve dementia diagnostic accuracy: a cross-sectional analysis.2026
6. Biomarkers in patients with clinical signs of mild cognitive impairment or mild Alzheimer's disease but without amyloid deposits on positron emission tomography: Results from Bio‐Hermes Study participantsAlzheimer s & Dementia · 2026
7. APOE ‐stratified Proteomic and Metabolomic Analysis Reveals Mitochondrial Dysfunction Inflammation and Lipid Dysregulation in Alzheimer's DiseaseAdvanced Science · 2026
8. Interchangeability of blood‐based biomarkers and PET to identify Alzheimer's disease pathologyAlzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · 2026
9. Cardiovascular Risk as a Moderator of the Relationship Between Plasma Alzheimer Disease Biomarkers and Cognitive StatusJournal of the American Heart Association · 2025
10. The Right Person, the Right Treatment, at the Right Time in Alzheimer's Disease: Insights From the 2025 Brain Aging SymposiumAging Cell · 2025
11. Plasma proteomic associations with Alzheimer’s disease endophenotypesNature Aging · 2025
12. Cardiovascular Risk as a Moderator of the Relationship of Plasma Alzheimer’s Disease Biomarkers with Cognitive StatusENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2025
13. Leaders at Italian Alzheimer’s Cafés addressing ethical issues: from advocacy response against human trafficking to Dolcezza approach with persons living with dementiaAging & Mental Health · 2024
14. The case for regulatory approval of amyloid‐lowering immunotherapies in Alzheimer's disease based on clearcut biomarker evidenceAlzheimer s & Dementia · 2024
15. Power, data and social accountability: defining a community‐led monitoring model for strengthened health service deliveryJournal of the International AIDS Society · 2024
16. Considerations for widespread implementation of blood‐based biomarkers of Alzheimer's diseaseAlzheimer s & Dementia · 2024
17. Recommendations for clinical implementation of blood‐based biomarkers for Alzheimer's diseaseAlzheimer s & Dementia · 2024
18. The Role of Strategic HRM in Strengthening Internal Brand Building in Higher Education InstitutionINTERANTIONAL JOURNAL OF SCIENTIFIC RESEARCH IN ENGINEERING AND MANAGEMENT · 2024
19. Facilitators and barriers to community-led monitoring of health programs: Qualitative evidence from the global implementation landscapePLOS Global Public Health · 2024
20. Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s DiseaseNature Reviews Neurology · 2024